Pham Cam Phuong1, LE Viet Nam2, Steven E Schild3, Dirk Rades4,5, Mai Trong Khoa2,5. 1. The Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam phamcamphuong@gmail.com. 2. The Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam. 3. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A. 4. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany. 5. Department of Nuclear Medicine, Ha Noi Medical University, Hanoi, Vietnam.
Abstract
AIM: To create a simple survival score for patients with high-grade gliomas based on clinical symptoms and performance status. PATIENTS AND METHODS: Thirty-six patients received neurosurgical intervention followed by radiochemotherapy for high-grade gliomas. Six pre-treatment symptoms were included in the score depending on their impairment of quality of life, scoring each between 1 and 3. For each patient, the points from the symptoms were added and another 4 points were added for Karnofsky performance status (KPS) <80%. Based on the survival rates of these scores, two groups were formed: 1-4 (group A) and 5-12 points (group B). RESULTS: The 1-, 2- and 3-year survival rates in group A were 100%, 33% and 24% in group A and 47%, 7% and 0% in group B (p<0.001). In addition, complete tumor resection (p<0.001) and tumor grade III (p<0.001) were associated with improved survival. CONCLUSION: A simple survival score was developed helping physicians in decision-making for patients with high-grade gliomas. Copyright
AIM: To create a simple survival score for patients with high-grade gliomas based on clinical symptoms and performance status. PATIENTS AND METHODS: Thirty-six patients received neurosurgical intervention followed by radiochemotherapy for high-grade gliomas. Six pre-treatment symptoms were included in the score depending on their impairment of quality of life, scoring each between 1 and 3. For each patient, the points from the symptoms were added and another 4 points were added for Karnofsky performance status (KPS) <80%. Based on the survival rates of these scores, two groups were formed: 1-4 (group A) and 5-12 points (group B). RESULTS: The 1-, 2- and 3-year survival rates in group A were 100%, 33% and 24% in group A and 47%, 7% and 0% in group B (p<0.001). In addition, complete tumor resection (p<0.001) and tumor grade III (p<0.001) were associated with improved survival. CONCLUSION: A simple survival score was developed helping physicians in decision-making for patients with high-grade gliomas. Copyright
Authors: Paolo Tini; Alfonso Cerase; Gabriele Cevenini; Salvatore F Carbone; Clelia Miracco; Luigi Pirtoli Journal: Anticancer Res Date: 2015-07 Impact factor: 2.480
Authors: D Rades; L Dziggel; B Segedin; I Oblak; V Nagy; A Marita; S E Schild; N T Trang; M T Khoa Journal: Strahlenther Onkol Date: 2013-06-07 Impact factor: 3.621
Authors: Judith Proske; Lisa Walter; Elisabeth Bumes; Markus Hutterer; Arabel Vollmann-Zwerenz; Ilker Y Eyüpoglu; Nicolai E Savaskan; Corinna Seliger; Peter Hau; Martin Uhl Journal: Anticancer Res Date: 2016-03 Impact factor: 2.480
Authors: Talia Wegman-Ostrosky; Nancy Reynoso-Noverón; Sonia I Mejía-Pérez; Thalía E Sánchez-Correa; Rosa María Alvarez-Gómez; Silvia Vidal-Millán; Bernardo Cacho-Díaz; José Sánchez-Corona; Luis A Herrera-Montalvo; Teresa Corona-Vázquez Journal: Clin Neurol Neurosurg Date: 2016-05-06 Impact factor: 1.876
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Seo Hee Choi; Jun Won Kim; Jee Suk Chang; Jae Ho Cho; Se Hoon Kim; Jong Hee Chang; Chang-Ok Suh Journal: Sci Rep Date: 2017-02-08 Impact factor: 4.379